invIOs to present at upcoming industry and investor conferences VIENNA, Austria, Oct. 11, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces its participation at three...

APEIRON shareholders approve new group structure geared towards enabling innovation and growth VIENNA, Austria, April 26, 2022 (GLOBE NEWSWIRE) -- APEIRON Biologics AG announces that the annual general meeting held yesterday has approved the new structure of the group through the demerger of...

invIOs to present at upcoming conferences VIENNA, Austria, Feb. 03, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, today announced the participation at three upcoming...

invIOs goes live with unique cell therapy platform and clinical-stage immuno-oncology pipeline VIENNA, Austria, Dec. 16, 2021 (GLOBE NEWSWIRE) -- invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for cancer, is pleased to announce it...